|
KMID : 1149120220190010014
|
|
Journal of the Korean Society for Psoriasis
2022 Volume.19 No. 1 p.14 ~ p.18
|
|
|
Analysis of Serial Interferon-gamma Release Assay Results in Patients with Psoriasis Receiving Biologic Treatment in Korea
|
|
Kim Sung-Min
Sung Jae-Young
Kim Chang-Yong
Cho Young-Ah
Yu Da-Ae
Lee Yang-Won
Choe Yong-Beom
|
|
|
Abstract
|
|
|
Background: Biologics are widely used for the treatment of moderate to severe psoriasis as their safety and efficacy have been determined. However, as biologics act as antagonists of Interleukin (IL) or Tumor necrosis factor-alpha (TNF-α), there are concerns regarding immunity to infectious diseases including tuberculosis (Tb).
Objectives: We analyzed the serial interferon-gamma release assay (IGRA) for detecting latent tuberculosis infection in patients treated with biologics (ustekinumab, secukinumab, guselkumab, ixekizumab) for psoriasis.
Methods: A retrospective analysis of IGRA results was performed during follow-up sessions of patients with psoriasis between January 2013 and March 2022.
Results: Among the total 122 patients, the initial IGRA results of 78 patients (63.9%) were negative and 44 patients (36.1%) were positive for Tb. During the 9 years of follow up, 3 patients (3.8%) of the 78 who were initially IGRA negative showed seroconversion and tested IGRA positive; 10 patients (22.7%) of the 44 patients who were initially IGRA positive showed seroreversion and tested IGRA negative. Of the three patients with seroconversion, none had active tuberculosis infection.
Conclusion: Seroconversion was observed in three patients treated by biologics in this study. Considering the epidemiologic characteristics of Korea having a high incidence rate of tuberculosis, annual follow-up examination along with preventive tuberculosis treatment is necessary.
|
|
|
KEYWORD
|
|
|
Biologics, Tuberculosis, Seroconversion, Seroreversion
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|